Search research articles
Contact Us
Filters
Showing results (111-120 of 125) with videos related to
Page
of 13
Sort By:
Leukemia & Lymphoma
|
January 29, 2021
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort
Talvinder Bhogal, Umair T Khan, Rebecca Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Hans Wildiers, Anne Armstrong, Eveline Cuypere, et al.
Obstetrics and Gynecology
|
August 3, 2023
Risks of Uterine Perforation and Expulsion Associated With Intrauterine Devices
Michael J Fassett, Susan D Reed, Kenneth J Rothman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2022
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Nigel Bundred, Nuria Porta, Adrian Murray Brunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1
Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial
Costanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.
American Journal of Obstetrics and Gynecology
|
April 8, 2022
Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study
Jennifer L Gatz, Mary Anne Armstrong, Debbie Postlethwaite, et al.
American Journal of Obstetrics and Gynecology
|
March 16, 2022
Association between menorrhagia and risk of intrauterine device-related uterine perforation and device expulsion: results from the Association of Uterine Perforation and Expulsion of Intrauterine Device study
Darios Getahun, Michael J Fassett, Jennifer Gatz, et al.
JAMA Network Open
|
February 28, 2022
Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion
Mary Anne Armstrong, Tina Raine-Bennett, Susan D Reed, et al.
Lancet (London, England)
|
April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 125) with videos related to
Sort By:
Page
of 13
Leukemia & Lymphoma
|
January 29, 2021
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort
Talvinder Bhogal, Umair T Khan, Rebecca Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Hans Wildiers, Anne Armstrong, Eveline Cuypere, et al.
Obstetrics and Gynecology
|
August 3, 2023
Risks of Uterine Perforation and Expulsion Associated With Intrauterine Devices
Michael J Fassett, Susan D Reed, Kenneth J Rothman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2022
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Nigel Bundred, Nuria Porta, Adrian Murray Brunt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1
Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial
Costanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.
American Journal of Obstetrics and Gynecology
|
April 8, 2022
Association between intrauterine device type and risk of perforation and device expulsion: results from the Association of Perforation and Expulsion of Intrauterine Device study
Jennifer L Gatz, Mary Anne Armstrong, Debbie Postlethwaite, et al.
American Journal of Obstetrics and Gynecology
|
March 16, 2022
Association between menorrhagia and risk of intrauterine device-related uterine perforation and device expulsion: results from the Association of Uterine Perforation and Expulsion of Intrauterine Device study
Darios Getahun, Michael J Fassett, Jennifer Gatz, et al.
JAMA Network Open
|
February 28, 2022
Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion
Mary Anne Armstrong, Tina Raine-Bennett, Susan D Reed, et al.
Lancet (London, England)
|
April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
Page
of 13